GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Cyclically Adjusted PB Ratio

Exact Sciences (STU:EXK) Cyclically Adjusted PB Ratio : 4.00 (As of Jun. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Cyclically Adjusted PB Ratio?

As of today (2024-06-02), Exact Sciences's current share price is €41.535. Exact Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €10.38. Exact Sciences's Cyclically Adjusted PB Ratio for today is 4.00.

The historical rank and industry rank for Exact Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:EXK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.41   Med: 16.3   Max: 43.88
Current: 3.9

During the past years, Exact Sciences's highest Cyclically Adjusted PB Ratio was 43.88. The lowest was 3.41. And the median was 16.30.

STU:EXK's Cyclically Adjusted PB Ratio is ranked worse than
73.88% of 134 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.915 vs STU:EXK: 3.90

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exact Sciences's adjusted book value per share data for the three months ended in Mar. 2024 was €15.676. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €10.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted PB Ratio Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.33 26.81 10.80 5.33 6.68

Exact Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.90 9.13 6.35 6.68 5.93

Competitive Comparison of Exact Sciences's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted PB Ratio falls into.



Exact Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Exact Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=41.535/10.38
=4.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Exact Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=15.676/131.7762*131.7762
=15.676

Current CPI (Mar. 2024) = 131.7762.

Exact Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.156 100.560 2.825
201409 2.007 100.428 2.633
201412 2.644 99.070 3.517
201503 2.683 99.621 3.549
201506 2.249 100.684 2.944
201509 3.342 100.392 4.387
201512 3.104 99.792 4.099
201603 2.649 100.470 3.474
201606 2.259 101.688 2.927
201609 2.978 101.861 3.853
201612 2.883 101.863 3.730
201703 2.603 102.862 3.335
201706 4.042 103.349 5.154
201709 3.698 104.136 4.680
201712 3.649 104.011 4.623
201803 4.572 105.290 5.722
201806 5.197 106.317 6.442
201809 4.998 106.507 6.184
201812 4.859 105.998 6.041
201903 5.327 107.251 6.545
201906 5.237 108.070 6.386
201909 5.234 108.329 6.367
201912 13.949 108.420 16.954
202003 15.367 108.902 18.595
202006 14.868 108.767 18.013
202009 13.195 109.815 15.834
202012 11.527 109.897 13.822
202103 17.894 111.754 21.100
202106 17.189 114.631 19.760
202109 17.063 115.734 19.428
202112 17.263 117.630 19.339
202203 16.852 121.301 18.307
202206 17.172 125.017 18.100
202209 17.713 125.227 18.639
202212 16.146 125.222 16.991
202303 15.881 127.348 16.433
202306 15.626 128.729 15.996
202309 16.175 129.860 16.414
202312 15.903 129.419 16.193
202403 15.676 131.776 15.676

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (STU:EXK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Exact Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.